ELI LILLY AND COMPANY Proceeds from Sale of Available-for-sale Securities
ELI LILLY AND COMPANY (LLY) reported Proceeds from Sale of Available-for-sale Securities of $5.77 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-20.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2018-02-20
- ELI LILLY AND COMPANY proceeds from sale of available-for-sale securities for fiscal 2017 was $5.77B, a 78.04% increase from fiscal 2016.
- ELI LILLY AND COMPANY proceeds from sale of available-for-sale securities for fiscal 2016 was $3.24B, a 31.54% decline from fiscal 2015.
- ELI LILLY AND COMPANY proceeds from sale of available-for-sale securities for fiscal 2015 was $4.73B, a 67.60% decline from fiscal 2014.
- ELI LILLY AND COMPANY proceeds from sale of available-for-sale securities for fiscal 2014 was $14.61B, a 6.22% increase from fiscal 2013.
| Period end | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|
| 2017-12-31 | $5.77B 10-K · filed 2018-02-20 |
| 2016-12-31 | $3.24B 10-K · filed 2018-02-20 |
| 2015-12-31 | $4.73B 10-K · filed 2018-02-20 |
| 2014-12-31 | $14.61B 10-K · filed 2017-02-21 |
| 2013-12-31 | $13.75B 10-K · filed 2016-02-19 |
| 2012-12-31 | $6.53B 10-K · filed 2015-02-19 |
| 2011-12-31 | $2.27B 10-K · filed 2014-02-19 |
| 2010-12-31 | $760.30M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |